

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



天津泰達生物醫學工程股份有限公司
Tianjin TEDA Biomedical Engineering Company Limited
(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 8189)

POLL RESULTS OF EXTRAORDINARY GENERAL MEETING

The Board is pleased to announce that all resolutions as set out in the EGM Notice dated 14 November 2022 was duly passed at the EGM held on 30 December 2022.

RESULTS OF THE EGM

Reference is made to the notice of extraordinary general meeting (the “**EGM Notice**”) and the circular (the “**Circular**”) of Tianjin TEDA Biomedical Engineering Company Limited (the “**Company**”), both dated 14 November 2022. Capitalised terms used herein shall have the same meanings as defined in the Circular unless the context requires otherwise.

The board of directors (the “**Board**”) is pleased to announce that all resolutions as set out in the EGM Notice was duly passed by way of poll at the extraordinary general meeting (the “**EGM**”) held on 30 December 2022.

As at the date of the EGM, the Company had 1,894,500,000 Shares in issue including 697,500,000 Domestic Shares and 1,197,000,000 H Shares. Prior to the date of the EGM, Shareholders holding 1,748,784,500 Shares, representing approximately 92.31% of the total number of the Shares in issue as at the date of the EGM, had notified to the Company that they will attend the EGM either in person or by proxy. The actual number of the Shares attending the EGM either in person or by proxy was 662,500,000, representing approximately 34.97% of the total number of the Shares in issue as at the date of the EGM. The holding of the EGM shall comply with the Company Law of the PRC and the Articles of Association.

No Shareholder was required to abstain from voting in respect of the resolution at the EGM. As such, there were a total of 1,894,500,000 Shares entitling the Shareholders to attend and vote on the resolution at the EGM.

There were no Shares entitling the Shareholders to attend and abstain from voting in favour of the resolution at the EGM as set out in Rule 17.47A of the GEM Listing Rules. No Shareholder has stated in his/her intention to vote against or to abstain from voting on any resolutions at the EGM.

Details of the poll results in respect of the resolution proposed at the EGM were as follows:

Resolutions		Number of Shares Represented by Votes (%)		Total Number of Shares
		For	Against	
(a)	To approve the ordinary resolution relating to the re-election of Ms. Sun Li as an executive director of the Company	662,500,000 shares 100%	0 share 0%	662,500,000 shares
(b)	To approve the ordinary resolution relating to the re-election of Mr. He Xin as an executive director of the Company	662,500,000 shares 100%	0 share 0%	662,500,000 shares
(c)	To approve the ordinary resolution relating to the re-election of Mr. Cao Aixin as a non-executive director of the Company	662,500,000 shares 100%	0 share 0%	662,500,000 shares
(d)	To approve the ordinary resolution relating to the re-election of Ms. Li Xueying as a non-executive director of the Company	662,500,000 shares 100%	0 share 0%	662,500,000 shares
(e)	To approve the ordinary resolution relating to the re-election of Mr. Li Ximing as a non-executive director of the Company	662,500,000 shares 100%	0 share 0%	662,500,000 shares
(f)	To approve the ordinary resolution relating to the re-election of Mr. Li Xudong as an independent non-executive director of the Company	662,500,000 shares 100%	0 share 0%	662,500,000 shares
(g)	To approve the ordinary resolution relating to the re-election of Mr. Wang Yongkang as an independent non-executive director of the Company	662,500,000 shares 100%	0 share 0%	662,500,000 shares
(h)	To approve the ordinary resolution relating to the re-election of Ms. Gao Chun as an independent non-executive director of the Company	662,500,000 shares 100%	0 share 0%	662,500,000 shares
(i)	To approve the ordinary resolution relating to the re-election of Ms. Yang Chunyan as a supervisor of the Company	662,500,000 shares 100%	0 share 0%	662,500,000 shares
(j)	To approve the ordinary resolution relating to the re-election of Ms. Liu Jinyu as a supervisor of the Company	662,500,000 shares 100%	0 share 0%	662,500,000 shares
(k)	To approve the ordinary resolution relating to the re-election of Mr. Liang Weitao as an independent supervisor of the Company	662,500,000 shares 100%	0 share 0%	662,500,000 shares

Resolutions		Number of Shares Represented by Votes (%)		Total Number of Shares
		For	Against	
(l)	To approve the ordinary resolution relating to the re-election of Mr. Zhao Zhiyou as an independent supervisor of the Company	662,500,000 shares 100%	0 share 0%	662,500,000 shares
(m)	To approve the ordinary resolution – the Board be authorized to negotiate and determine the remuneration and the terms and conditions of, and to sign the service contract with each of the proposed Directors and Supervisors on behalf of the Company	662,500,000 shares 100%	0 share 0%	662,500,000 shares
(n)	To approve the special resolution – THAT Article 20 to the Articles of Association of the Company be amended as the followings upon having obtained the approval of the Shareholders of the Company and the fulfilment of filing requirements with the Administration of Industry and Commence: The Company initiated the establishment and issued a total of 1,894,500,000 ordinary shares after several times of capital increase, including 697,500,000 Domestic Shares, representing 36.82% of the Company’s total issuable ordinary shares, and 1,197,000,000 overseas listed foreign shares, representing 63.18% of the Company’s total issuable ordinary shares. The share capital structure of the Company is as follows: 1,894,500,000 ordinary shares, in which 697,500,000 shares are Domestic Shares, of which (1) 14,000,000 shares are held by the promoter, Gu Hanqing, (2) 9,000,000 shares are held by the promoter, Xie Kehua. 674,500,000 shares held by the other Domestic Shares holders. 1,197,000,000 shares held by shareholders of overseas listed foreign shares.	662,500,000 shares 100%	0 share 0%	662,500,000 shares

Resolutions		Number of Shares Represented by Votes (%)		Total Number of Shares
		For	Against	
(o)	To approve the special resolution – THAT Article 12 to the Articles of Association of the Company be amended as the followings upon having obtained the approval of the Shareholders of the Company and the fulfilment of filing requirements with the Administration of Industry and Commence: The scope of business of the Company shall be in accordance with the approval issued by the company registration authority of the People’s Republic of China. General items: the development of medical researches and tests; sales of Category II medical devices; sales of Category I medical devices; manufacturing of Category I medical devices; research and development of biological organic fertilizers; research and development of compound micro-organism fertilizers; research and development of technology for bio-chemical products; sales of fertilizers; sales of agricultural machineries; sales of agricultural films; sales of feeds for fisheries and livestock industries; crop straw treatment and processing and utilization services; technology service, technology development, technology consultation, technology exchanges, technology transfer, technology promotion; elderly care service; nursing institution service (excluding medical service); health consultation service (excluding diagnose service); housekeeping service; conference and exhibition service; corporate image planning; advertisement preparation; advertisement publication; advertisement design and agency; sale of food (only prepackaged food); sale of food through online channels (only pre-packaged food); sale of pre-packaged foods, dairy products, powdered infant formula, special medical formula food. (Other than those which are subject to approval in accordance with the law, operating activities can be commenced with business licence) Licensed items: crop seeds operation (operations subject to approval in accordance with the law can only carry out operating activities after being approved by relevant departments, and the specific operations are subject to the approval or licenses of the relevant departments) (Not allowed to invest in the areas prohibited from foreign investment in the Negative List for Admission of Foreign Investment)	662,500,000 shares 100%	0 share 0%	662,500,000 shares

Note: The percentages of votes are calculated based on the total number of the Shares held by the Shareholders who voted at the EGM either in person or by corporate representative or proxy.

As more than half of the votes present at the EGM either in person or by proxy had voted in favour of the above ordinary resolutions numbered (a) to (m), the above resolutions were duly passed as ordinary resolutions.

As more than two-thirds of the votes present at the EGM either in person or by proxy had voted in favour of the above special resolutions numbered (n) and (o), the above resolution was duly passed as special resolutions.

Tianjin Zhong Yue CPA Firm (天津中悅會計師事務所), the Company's external accountant who is qualified to serve as its auditor was appointed as the scrutineer of the EGM for the vote-taking.

By order of the Board
Tianjin TEDA Biomedical Engineering Company Limited
Sun Li
Chairman

Tianjin, the PRC
30 December 2022

As at the date of this announcement, the executive directors of the Company are Sun Li, Hao Zhihui and He Xin; the non-executive directors of the Company are Cao Aixin, Li Xueying and Li Ximing; the independent non-executive directors of the Company are Li Xudong, Wang Yongkang and Gao Chun.

This announcement, for which the directors are willing to collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief that the information contained in this announcement is accurate and complete in all material respects and is not misleading or deceptive, and there are no other matters the omission of which would make this announcement or any statement herein misleading.

This announcement will remain on the GEM website at <http://www.hkgem.com> on the "Latest Company Announcements" page for 7 days from the date of its posting, and it will also be published and remain on the website of the Company at www.bioteda.com.